Anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents have permanently modified the landscape of therapeutic options in multiple chronic auto-inflammatory diseases such as inflammatory bowel diseases (IBD), rheumatoid arthritis (RA), and psoriasis [1]. The gene discussed is TNF; the disease is psoriasis.